AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...

The agency also approved acalabrutinib as part of combination therapy for mantle cell lymphoma. The FDA approved two oncology regimens on Jan. 16. One is for a subset of patients with colorectal ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...